Enhancement of Oral Bioavailability of Puerarin by Polybutylcyanoacrylate Nanoparticles

Table 1

Main pharmacokinetic parameters of PUE suspension and PUE-PCBN in rats.

Parameters	Unit	Value (mean ± SD)
		PUE suspension	PUE-PCBN
AUC(0-∞)	mg/L·h	1.216 ± 0.158	6.765 ± 2.374**
MRT(0-∞)	h	3.864 ± 0.832	6.299 ± 0.925**
T 1/2	h	2.409 ± 0.791	3.937 ± 0.972*
Vz	L/kg	85.41 ± 21.63	28.33 ± 13.95**
CL	L/h·kg	25.04 ± 3.489	4.936 ± 1.810**
𝐶𝑚𝑎𝑥	mg/L	0.363 ± 0.045	0.897 ± 0.135**

**Comparing to PUE suspension group, 𝑃<0.001; *Comparing to PUE suspension group, 𝑃<0.05.